Drug | Study type | Target | Drug action in the liver | References | |
---|---|---|---|---|---|
AS605240 | preclinical | PCI mouse model | PI3K-γ | Biotransformation | (Press et al. 2021) |
Dexmedeto-midine | preclinical | LPS rat model | TLR-4 | TLR4/MyD88/NF-κB signaling downregulation | (Zi et al. 2019) |
MCPIP1 | preclinical | LPS mouse model | miR-9 SIRT-1 | Decrease of Sirtuin1 in KC | (Zi et al. 2019) |
Montelukast | preclinical | LPS rat model | Blockage of leukotriene receptor | Anti-inflammatory properties Lowered TNF-alpha levels Limitation of liver injury | (Donkers et al. 2019) |
Pemafibrate | preclinical | CLP mouse model | PPAR-alpha | Reduction of accumulation of toxic lipid peroxidation products and cell death in liver | (Wyngene et al. 2020 Feb) |
Resveratrol | preclinical | CLP rat model | SIRT-1 | Inhibition of HMGB1 release | (González-Regueiro et al. 2020) |
UAMC-3203 | preclinical | CLP mouse model | Ferroptosis | Ferroptosis inhibition | (Coillie et al. 2022) |
Vilobelimab | clinical | Multicenter, randomized, and placebo-controlled study | Neutralization of C5a | Decrease of IL-8, IL-10 | (Bauer et al. 2021) (NCT02246595) |
Wogonin | preclinical | LPS- and CLP mouse model | Nrf2 | Anti-oxidative effects Inhibition of NF-κB-regulated pro-inflammatory signaling | (Dong et al. 2015) |